# AMPLATZER PFO Occluder Post Approval Study

Study · id `cardio:ct-nct03309332` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03309332](<https://clinicaltrials.gov/study/NCT03309332>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03309332

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1214 participants.

## Technical summary

Registry record NCT03309332. Allocation not applicable; no masking; primary purpose prevention. Start 2018-01-31 (actual); primary completion 2030-02-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 1214 participants (enrolled count; ClinicalTrials.gov record NCT03309332, source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)
- Started: 2018-01-31 (actual) (ClinicalTrials.gov record NCT03309332, source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)
- Primary completion: 2030-02-05 (anticipated) (ClinicalTrials.gov record NCT03309332, source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)
- Completion: 2030-02-05 (anticipated) (ClinicalTrials.gov record NCT03309332, source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Italy; Portugal; Switzerland; United Kingdom (ClinicalTrials.gov record NCT03309332, source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03309332-2026-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: AMPLATZER PFO Occluder Post Approval Study
- Acronym: PFO PAS
- Condition: Stroke
- Condition: Patent Foramen Ovale
- Intervention (Device): AMPLATZER™ PFO Occluder
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: b6a70c9698798da0ff756d97c79e50365940652c6482e64c1ccd6ff38b975496
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
